U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Drug Depot, Inc., dba APS Pharmacy - 501069 - 09/20/2019
  1. Warning Letters

CLOSEOUT LETTER

Drug Depot, Inc., dba APS Pharmacy MARCS-CMS 501069 —

Delivery Method:
UPS Overnight
Product:
Drugs
Recipient:
Recipient Name
Jaime A. Rios
Recipient Title
Co-Owner and President
Drug Depot, Inc., dba APS Pharmacy

34911 US Highway 19 N Ste 600
Palm Harbor, FL 34684-1921
United States

Issuing Office:
Center for Drug Evaluation and Research

4040 N. Central Expressway
Suite 300
Dallas, TX 75204
United States

Mr. Rios:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL # FLA-17-02; December 15, 2016). Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
John W. Diehl, M.S
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

Back to Top